RA Ventures – Technologies, Assets & Projects
The Company holds exclusive licenses from leading Universities and holds a part of the IP.
As an early-stage company, in order to reduce overhead costs, we effectively act as the project manager – we plan the assays together with the universities and subcontract the early development stages to university labs, and the later stages to CROs that specialize in the different fields. The Company monitors the results, determines next steps and fundraises for the next phases of development. We believe that working with leading experts at CROs is critical for success.
The Company has licenses for platform technologies which are progressing to several different projects; as such it is planning to out-license at various stages of development.
Synthesis of cyclic peptides which are peptidomimetics
RA Ventures has the capability to identify “active regions” of proteins and peptides, to isolate them and to turn them into cyclic peptides which are selective for the desired receptors and stable, thereby preventing off-target activation and adverse effects.
Drug delivery systems for peptides and other macromolecules
RA Ventures has a novel technology of coated liposomes for the oral delivery of peptide, ADC's, PDC's and other macromolecules such as genes (RNA, DNA), antibodies, enzymes etc. that achieves an unprecedented bioavailability.
A novel smart multi-armed linker for targeted drug delivery
Our linker can be used for peptide-drug conjugates (PDC's), antibody-drug conjugates (ADC's) and nanoparticle-drug conjugates (NDC's). Our linker releases the payload (chemotherapeutic drug or fluorescent) only in the tumor cells and can bind up to three payloads. We have demonstrated that using two or three different drug payloads kills the tumor cells more potently and with less drug resistance developing.
Discovery of novel peptides for
Peptide-Drug Conjugates
We have technologies to synthesize novel peptides which will bind to receptors overexpressed in certain tumors so that we will be able to use them for synthesizing peptide-drug conjugates (PDCs) to diagnose and treat different tumors. We already have at our disposal peptides that bind to the five different somatostatin receptors (overexpressed in pancreatic, gallbladder, breast, ovary, prostate, melanoma, lymphoma, glioblastoma, colon and non-small-cell lung tumors) and to certain integrin receptors (overexpressed in tumors such as breast, glioblastoma, leukemic cells).
Mission of the company
Rely on evidence-based medicine, analyse, figure out the science, think outside the box, innovate and solve problems in order to improve and prolong people’s lives, reduce morbidity and mortality.
